USPTO Issues 14-3-3η Patent: Good News for RA Patients

USPTO Issues 14-3-3η Patent: Good News for RA Patients

NEWS RELEASE | OCTOBER 17, 2017 Vancouver, BC —  Augurex Life Sciences Corp is proud to announce that 14-3-3η, a novel rheumatoid arthritis (RA) biomarker, is paving a future for better patient outcomes.  Today the U.S Patent and Trademark Office (USPTO) has issued...
Accelerating the Transformation of Patient Care

Accelerating the Transformation of Patient Care

Please see the Genome BC news release from last week. Augurex is proud of and appreciates the ongoing support that we receive from provincial and federal government programs to expedite JOINTstat™ access to patients worldwide. Augurex is recognized as an emerging...
14-3-3η: Informing the RA Continuum of Care

14-3-3η: Informing the RA Continuum of Care

14-3-3η Informs the RA Continuum of Care Vancouver, BC – October 28, 2016. At the world’s premier rheumatology conference, the American College of Rheumatology Annual Meeting (ACR) in Washington, DC, November 11-16, international investigators from Sweden, the United...